2.25
-0.25
(-10.00%)
May 20 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 2.25 - 2.40 |
| 52 week | 1.75 - 4.25 |
| Open | 2.50 |
| Vol / Avg. | 59,000.00/81,184.00 |
| Mkt cap | 3.17M* |
| P/E | 40.18 |
| Div/yield | - |
| EPS | 0.00* |
| Shares | 140.87M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jun 24, 2013
Interim 2013 Mediwatch PLC Earnings Release
Apr 22, 2013
Mediwatch PLC Annual General Meeting
|
|
Key stats and ratios
| Q4 (Oct '12) | 2012 | |
| Net profit margin | 0.82% | 0.79% |
| Operating margin | 1.52% | 1.53% |
| EBITD margin | - | 2.40% |
| Return on average assets | 0.91% | 0.89% |
| Return on average equity | 1.36% | 1.34% |
| Employees | 64 | - |
| Carbon Disclosure Rating | - | - |
Address
Lumonics House Valley Drive, Swift Valley
RUGBY, ENG CV21 1TQ
United Kingdom - Map
+44-1788-547888 (Phone)
+44-1788-536434 (Fax)
RUGBY, ENG CV21 1TQ
United Kingdom - Map
+44-1788-547888 (Phone)
+44-1788-536434 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Mediwatch Plc is a United Kingdom-based holding Company. The Company is engaged in the development and marketing of medical devices used in the diagnosis of urological disorders and early prostate cancer detection. The Company has two business units the United States of America and International/the United Kingdom. The Company�s subsidiaries include Medi-Watch UK Limited, which is engaged in the sale and marketing of urology products and services; Mediwatch USA Inc., which is engaged in the sale and marketing of urology products and services and Mediwatch Biomedical Limited, which is engaged in the development of medical diagnostic devices.
Officers and directors
| Philip G. Stimpson | Chief Executive Officer, Executive Director | |
| Mark Leonard William Hughes | Chief Financial Officer, Executive Director | |
| Omer M. A. Karim | Non-Executive Chairman of the Board | |
| Charles Enea Cattaneo | Non-Executive Director | |
| Mark Emberton M.D. | Non-Executive Medical Director |